Dr. Scott Ripley

Scott Ripley is a seasoned biotechnology executive with deep expertise in commercial strategy, bioprocessing, and advanced therapeutics. With over two decades in the industry, he has led global commercial teams and driven market growth across bioprocessing, nucleic acid therapeutics, and more recently, nanomedicine. As Vice President of Nucleic Acids and Nanomedicine at Cytiva, he oversaw the integration of Precision Nanosystems into Cytiva, and is expanding solutions for mRNA, lipid nanoparticles, and advanced therapies. Previously, he held senior leadership roles at GE Healthcare, including Global Marketing Director for Bioprocess and, where he played a key role in advancing biomanufacturing capabilities supporting both strategy and marketing demand generation. Beyond his corporate role, he serves as Chairperson of the Board at Testa Center, fostering biotech innovation in Sweden. With a Ph.D. from the University of Cambridge, Scott is passionate about translating cutting-edge science into real-world impact, advancing next-generation therapeutics for global healthcare. Scott is currently based in Uppsala, Sweden.